Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells

Hepatobiliary and Pancreatic Diseases International

Volumn 5, Issue 1, 2006, Pages 96-100

  Li, Tao ^a   Weng, Shan Geng ^a   Leng, Xi Sheng ^a   Peng, Ji Run ^a   Wei, Yu Hua ^a   Mou, Dong Cheng ^a   Wang, Wan Xiang ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

5 hydroxytamine; Hepatic stellate cell; Receptor; Transforming growth factor

Indexed keywords

COLLAGENASE; KETANSERIN; MESSENGER RNA; ONDANSETRON; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG EFFECT; EX VIVO STUDY; LIVER CELL; LIVER CIRRHOSIS; LIVER PERFUSION; MALE; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; GENE EXPRESSION; KETANSERIN; LIVER; LIVER CIRRHOSIS; MALE; ONDANSETRON; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SEROTONIN; SEROTONIN ANTAGONISTS; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33644542711     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Reynaert H, Thompson MG, Thomas T. Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-581.
2. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001;21:337-349.
3. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999;14:618-633.
4. 2 receptor subtypes: A family reunited? Trends Pharmacol Sci 1995; 16:105-110.
5. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharcacol Rev 1994;46:157-203.
6. 2A receptor. Am J Physiol 1995;268:F122-F127.
7. Didier L. Current status and future goals of the pharmacologic reduction of portal hypertension. Am J Surg 1990;160:19-25.
8. Ramm GA. Isolation and culture of rat hepatic stellate cells. J Gastroenterol Hepatol 1998;13:846-851.
9. Knittel T, Mehde M, Kobold D. Expreeion patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999;30:48-60.
10. Pinzani M, Gentilini A, Caligiuri A. Transforming growth factor-beta 1 regulates platelet-derived growth factor receptor beta subunit in human liver fat-storing cells. Hepatology 1995;21:232-239.
11. Castilla A, Prieto J, Fausto N. Transforming growth factor beta 1 and alpha in chronic liver disease. Effects of interferon alpha therapy. N Engl J Med 1991;324:933-940.
12. Watts SW, Yang P, Banes AK, Baez M. Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors. J Cardiovascu Pharmaco 2001;38:539-551.
13. Liu JS. G-couple receptor. In: Liu JS eds. Cell signaling and regulation. Beijing. Beijing: Medical University and Peking Union Medical College Publishing House; 1998.
14. Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, et al. Serotonin enhances the production of type IV collagen by human mesangial cells. Kid Inter 1998;54: 1083-1092.
15. 2 receptor subtypes in human coronary arteries. Cardiovascu Res 1999; 41:267-274.